Effects of Beraprost Sodium (Dorner®) in Patients with Diabetes Mellitus Complicated by Chronic Arterial Obstruction

Abstract

The effects of the prostaglandin I₂ derivative beraprost sodium (Dorner^®) on ankle pressure index (API; ankle joint-to-upper extremity systolic pressure ratio), subjective symptoms, and intermittent claudication were investigated in diabetic patients with arteriosclerosis obliterans (ASO). Forty patients (25 men and 15 women), mean age 63.9 years, were enrolled in this study. ASO was grade I in 30 patients, grade II in seven, grade III in one, and grade IV in two according to the Fontaine classification. They were administered six tablets (20 μg/tablet) of beraprost sodium daily for 6 months. At 3 and 6 months, API had significantly increased and symptoms such as coldness, numbness, and lack of feeling in the lower extremities were significantly improved. Ten evaluable patients increased ambulatory distance by approximately threefold, suggesting an improvement in intermittent claudication. Adverse reactions were experienced by five (12.5%) of the 40 patients (one case each of headache, dull headache, pain in the posterior region of the neck, heartburn, stomach discomfort, and anemia), but all were mild and resolved without treatment. Beraprost sodium was shown to improve API and symptoms in the lower extremities in diabetic patients with ASO, suggesting that it is useful in treating peripheral circulatory disorders in such patients.

Get full access to this article

View all access options for this article.

References

Hidaka H. , Nakajima Y. , Aoki T. , et al: Study on the clinical picture of peripheral angiopathy in diabetes mellitus. J Jpn Diabetic Soc 32:195-201, 1989.

Nishio S. : Pharmacology of beraprost sodium. Mod Med Care 24(suppl):109-117, 1992.

Ueno Y. , Yamada N. , Koike H. , Nishio S. : Effects of beraprost sodium and prostaglandin E1 on skin blood flow in diabetic rats and normal dogs. Gen Pharmacol 27:333-335, 1996.

Saito Y. , Shinomiya M. , Masuyama Y. , et al: Effect of beraprost sodium on balloon catheterization-induced intimal thickening in the rabbit carotid artery. Mod Med Care 24(suppl):148-152, 1992.

Sasaki R. , Tamakoshi Y. , Ogawa Y. , et al: Effect of beraprost sodium, a stable type prostacyclin derivative, in a rat model of intimal thickening. Thromb Circ 4:86-90, 1996.

Sakaguchi S. : Clinical study of beraprost sodium, a new oral prostacyclin (PGI2) derivative. Mod Med Care 24(suppl):119-134, 1992.

Sakuma M. , Yasuda K. , Matsui Y. , et al: Clinical assessment of beraprost sodium in chronic arterial obstruction. Geriat Med 33:357-363, 1995.

Aoki T. , Yamaguchi T. , Ueda N. , et al: Effect of an oral PGI2 derivative on peripheral circulation . Geriat Med 34:129-133, 1995.

Toyota T. , Oikawa S. , Satoh T. , et al: Efficacy of beraprost sodium against chronic arterial obstruction in patients with concomitant diabetes. Endocrinol Diabetol 1:104-118, 1999.

10.

Fontaine R. , Kim M. , Kieny R. : Surgical treatment of peripheral circulatory disorders. Chir Acta 21:499, 1954.

11.

Matsuo H. : Prediction of intermittent claudication and early diagnosis. Clin Sci 28:1524, 1992.

12.

Beks PJ , Mackaay Ajc , de Neeling Jnd , et al: Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: The Hoorn Study. Diabetologia 38:86-96, 1995.

13.

Okuda Y. , Sone H. , Mizutani S. , et al: Acute effect of beraprost sodium on lower limb circulation in patients with non insulin dependent diabetes mellitus—evaluation by color Doppler ultrasonography and laser cutaneous blood flowmetry. Prostaglandins 52:375-384, 1996.

14.

Ishii N. , Nakajima H. , Kato Y. , Yoshida S. : Evaluation of therapeutic effect of beraprost sodium (Dorner®) on skin ulcer . Nishi Nihon J Dermatol 59:103-106, 1997.

15.

Yamamori I. , Hasegawa H. , Tachikawa K. , et al: Effect of beraprost sodium on various metabolism parameters in arteriosclerosis obliterans. Endocrinol Diabetol 3:200-208, 1996.